Pharma Reviews: Pharma sector revenue, margins likely to remain healthy in FY2022: ICRA

... inelastic demand for drugs and resumption of production to the near pre-Covid levels by Q3 FY2021, revenue growth for IPM (Indian Pharmaceutical ...
Read more: Pharma sector revenue, margins likely to remain healthy in FY2022: ICRA